Advertisement

An Overview of Alzheimer’s Disease Research

  • Zaven S. Khachaturian
    Correspondence
    Requests for reprints should be addressed to Zaven Khachaturian, PhD, 8912 Copenhaver Drive, Potomac, Maryland 20854
    Affiliations
    Khachaturian, Radebough and Associates, an International Consulting Group on Alzheimer’s Disease, Potomac, Maryland, USA
    Search for articles by this author
      The emergence of Alzheimer’s disease (AD) as one of the major public health issues for the 21st century is being shaped by the changing trends in population demography, health economics, and the overall health status of the US population. Among the many factors influencing the magnitude and nature of this public heath problem are: (1) an increasing number of older individuals at risk for AD
      • Payami H.
      • Grimslid H.
      • Oken B.
      • Camicioli R.
      • et al.
      A prospective study of cognitive health in the elderly (Oregon Brain Aging Study) effects of family history and apolipoprotein E genotype.
      ; (2) the rising cost of long-term care
      • Manton K.G.
      • Corder L.
      • Stallard E.
      Chronic disability trends in elderly United States population.
      ; and (3) the increase in the duration of AD disability (since people are living longer).
      • Payami H.
      • Grimslid H.
      • Oken B.
      • Camicioli R.
      • et al.
      A prospective study of cognitive health in the elderly (Oregon Brain Aging Study) effects of family history and apolipoprotein E genotype.
      The “baby boom” generation will soon reach an age where they are at risk for dementia. It is projected that the future cohorts of at-risk populations will be much healthier, better educated, and have a longer life expectancy with fewer physical disabilities, except for dementia.
      • Manton K.G.
      • Corder L.
      • Stallard E.
      Chronic disability trends in elderly United States population.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Payami H.
        • Grimslid H.
        • Oken B.
        • Camicioli R.
        • et al.
        A prospective study of cognitive health in the elderly (Oregon Brain Aging Study).
        Am J Hum Genet. 1997; 60: 948-956
        • Manton K.G.
        • Corder L.
        • Stallard E.
        Chronic disability trends in elderly United States population.
        Proc Natl Acad Sci USA. 1997; 94: 2593-2598
        • Anastas J.
        • Gibeau J.
        • Larson P.
        Working families and eldercare.
        Social Work. 1990; 6: 385-480
        • Mortimer J.
        Epidemiology of dementia.
        in: Brody J.A. Maddox G.I. Epidemiology and Aging An International Perspective. Springer, New York1988: 150-164
        • Evans D.A.
        Descriptive epidemiology of Alzheimer’s disease.
        in: Khatchaturian Z.S. Radebaugh T.S. Alzheimer’s Disease Causes, Diagnosis, Treatment, and Care. CRC Press, Boca Raton, Fla1996
        • Khachaturian Z.S.
        Diagnosis of Alzheimer’s disease.
        Arch Neurol. 1985; 42: 1097-1105
        • Braak H.
        • Braak E.
        Neuropathological staging of Alzheimer-related changes.
        Acta Neuropathol. 1991; 82: 239-259
        • Roses A.D.
        Alzheimer’s disease. the genetics of risk.
        Hosp Pract. 1997; 32: 51-55
        • Poirier J.
        Apolipoprotein E in the brain and its role in Alzheimer’s disease.
        J Psychiatry Neurosci. 1996; 21: 128-134
        • Payami H.
        • Schellenberg G.D.
        • Zareparsi S.
        • et al.
        Evidence for association of HLA-A2 allele with onset age of Alzheimer’s disease.
        Neurology. 1997; 49: 512-518
        • Braak H.
        • Braak E.
        Aspects of cortical destruction in Alzheimer’s disease.
        in: Hyman B.T. Duyckaerts C. Christen Y. Connections, Cognition, and Alzheimer’s Disease. Springer-Verlag, Heidelberg, Germany1997
        • Snowdon D.A.
        • Kemper S.J.
        • Mortimer J.A.
        • Greiner L.H.
        • Wekstein D.R.
        • Markesbery W.R.
        Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life. Findings from the Nun Study.
        JAMA. 1996; 275: 528-532
        • Reiman E.M.
        • Caselli R.J.
        • Yun L.S.
        • Chen K.
        • et al.
        Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
        N Engl J Med. 1996; 334: 752-758
        • Fox N.
        • Freeborough P.A.
        • Rossor M.N.
        Visualization and quantification of rates of atrophy in Alzheimer’s disease.
        Lancet. 1996; 348: 94-97
        • Morris J.C.
        Differential diagnosis of Alzheimer’s disease.
        in: Khachaturian Z.S. Radebaugh T.S. Alzheimer’s Disease Causes, Diagnosis, Treatment, and Care. CRC Press, Boca Raton, Fla1996
        • Gibson G.
        • Martins R.
        • Blass J.
        • Gandy S.
        Altered oxidation and signal transduction systems in fibroblasts from Alzheimer patients.
        Life Sci. 1996; 59: 477-489
        • Berg L.
        • Morris J.C.
        Diagnosis.
        in: Terry R.D. Katzman R. Bick K.L. Alzheimer’s Disease. Raven Press, New York1994
        • Kalaria R.N.
        • Cohen D.L.
        • Premkumar D.R.
        Apolipoprotein E alleles and brain vascular pathology in Alzheimer’s disease.
        Ann NY Acad Sci. 1996; 777: 266-270
        • Thomas T.
        • Thomas G.
        • Mclendon C.
        • Sutton T.
        • Mullan M.
        Beta-amyloid-mediated vasoactivity and vascular endothelial damage.
        Nature. 1996; 380: 168-171
        • Hensley K.
        • Carney J.M.
        • Mattson M.P.
        • et al.
        A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide.
        Proc Natl Acad Sci USA. 1994; 91: 3270-3274
        • St. George-Hyslop P.H.
        • Haines J.L.
        • Farrer L.A.
        • et al.
        Genetic linkage studies suggest that Alzheimer’s disease is not a single homogeneous disorder.
        Nature. 1990; 347: 194-197
        • Sherrington R.
        • Rogaev E.I.
        • Liang Y.
        • et al.
        Cloning of a gene bearing mis-sense mutations in early-onset familial Alzheimer’s disease.
        Nature. 1995; 375: 754-760
        • Mullan M.
        • Crawford F.
        • Axelman K.
        • et al.
        A pathogenetic mutation for probable AD in the APP gene at the N-terminus of β-amyloid.
        Nature Gen. 1992; 1: 345-347
        • Levy-Lahad E.
        • Wasco W.
        • Poorkaj
        • et al.
        Candidate gene for the chromosome 1 familial Alzheimer’s disease locus.
        Science. 1995; 269: 973-977
        • Bird T.D.
        • Levy-Lahad E.
        • Poorkaj P.
        • et al.
        Wide range in age of onset for chromosome 1-related familial Alzheimer’s disease.
        Ann Neurol. 1996; 40: 932-936
        • Saunders A.M.
        • Strittmatter W.J.
        • Schmechel D.
        • George-Hyslop P.H.
        Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease.
        Neurology. 1993; 43: 1467-1472
        • Higgins G.A.
        • Large C.H.
        • Rupniak H.T.
        • Barnes J.C.
        Apolipoprotein E and Alzheimer’s disease.
        Pharmacol Biochem Behav. 1997; 56: 675-685